ArticleMilitary medicine2019
4-Aminopyridine as a Single Agent Diagnostic and Treatment for Severe Nerve Crush Injury.
Article in Military medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Cracking the code: the clinical and molecular impact of aminopyridines; a review (2019-2024).RSC advances · 2025Review
- GCPII Inhibition Promotes Remyelination after Peripheral Nerve Injury in Aged Mice.International journal of molecular sciences · 2024Article
- Neuromodulators can promote nerve regeneration and accelerate functional recovery after peripheral nerve injury: A systematic review.Journal of orthopaedics · 2024Review
- Effects of 4-Aminopyridine on Combined Nerve and Muscle Injury and Bone Loss.The Journal of hand surgery · 2023Article
- 4-Aminopyridine Protects Nigral Dopaminergic Neurons in the MPTP Mouse Model of Parkinson's Disease.Neurochemical research · 2023Article
- Functional recovery and muscle atrophy in pre-clinical models of peripheral nerve transection and gap-grafting in mice: effects of 4-aminopyridine.Neural regeneration research · 2023Article
- Pathophysiology of Spinal Cord Injury and Tissue Engineering Approach for Its Neuronal Regeneration: Current Status and Future Prospects.Advances in experimental medicine and biology · 2023Review
- Electrodiagnostic Evaluation of Prognostic Factors Influencing the Surgical Outcomes of Upper Extremity Nerve Injuries Caused by Penetrating Trauma: A Cross-sectional Study.World journal of plastic surgery · 2023Article
- 4-Aminopyridine Induces Nerve Growth Factor to Improve Skin Wound Healing and Tissue Regeneration.Biomedicines · 2022Article
- Simultaneous triple-parametric optical mapping of transmembrane potential, intracellular calcium and NADH for cardiac physiology assessment.Communications biology · 2022Article
- Biopolymer-nanotube nerve guidance conduit drug delivery for peripheral nerve regeneration:Bioactive materials · 2021Article
- Phase IIB Randomized Trial on the Use of 4-Aminopyridine in Guillain-Barré Syndrome.Archives of rehabilitation research and clinical translation · 2021Article
- Neuroprotective Properties of 4-Aminopyridine.Neurology(R) neuroimmunology & neuroinflammation · 2021Review
- 4-Aminopyridine: A Single-Dose Diagnostic Agent to Differentiate Axonal Continuity in Nerve Injuries.Military medicine · 2021Article
- Human equivalent dose of oral 4-aminopyridine differentiates nerve crush injury from transection injury and improves post-injury function in mice.Neural regeneration research · 2020Article
- Peripheral nerve injury and myelination: Potential therapeutic strategies.Journal of neuroscience research · 2020Review
- Transdermal delivery of 4-aminopyridine accelerates motor functional recovery and improves nerve morphology following sciatic nerve crush injury in mice.Neural regeneration research · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
backgroundTraumatic peripheral nerve injury (TPI) is a major medical problem without effective treatment options. There is no way to diagnose or treat an incomplete injury and delays contribute to morbidity. We examined 4-aminopyridine (4-AP), a potassium-channel blocker as a possible treatment for TPI.
methodsWe used standard mouse models of TPI with functional outcomes including sciatic-functional-index, sensory indices, and electrodiagnostics; in addition to standard immunohistochemical, and electron microscopic correlates of axon and myelin morphology.
resultsSustained early 4-AP administration increased the speed and extent of behavioral recovery too rapidly to be explained by axonal regeneration. 4-AP also enhanced recovery of nerve conduction velocity, promoted remyelination, and increased axonal area post-injury. 4-AP treatment also enabled the rapid distinction between incomplete and complete nerve lesions.
conclusion4-AP singularly provides both a new potential therapy to promote durable recovery and remyelination in acute peripheral nerve injury and a means of identifying lesions in which this therapy would be most likely to be of value. The ability to distinguish injuries that may respond to extended therapy without intervention can offer benefit to wounded soldiers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.